Case Studies
Clovis Oncology
Clovis Oncology has chosen Quotient’s drug product optimization approach for rociletinib, a promising oral candidate drug for the treatment of EGFR-resistant non-small cell lung cancer.
Register now for our 'Achieving Proof-of-Concept' European Seminar Series
Case Studies
Clovis Oncology has chosen Quotient’s drug product optimization approach for rociletinib, a promising oral candidate drug for the treatment of EGFR-resistant non-small cell lung cancer.